EUVIMEDEUVIMED entdecken
Crossref

Nerve Growth Factor and Brain-Derived Neurotrophic Factor as Potential Biomarkers of Mirabegron Efficacy in Patients with Overactive Bladder Syndrome

Anastasia Beta iD, Aikaterini Giannouli, Demetrios Rizos, Aimilia Mantzou, Efthymios Deligeoroglou, Panagiotis Bakas

International Urogynecology Journal · 2024-06 · 35 (6) · 1317-1322

DOI: 10.1007/s00192-024-05809-0 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Urogynecology Journal, online erschienen am 18.05.2024. Verfasst von Anastasia Beta und 5 weiteren Autor:innen. Beteiligte Einrichtung: 2nd Department of Obstetrics and Gynecology, Athens University, Medical School, Aretaieion Hospital, Vasilissis Sofias Avenue, 76, 11528, Athens, PC,…. Hauptthemen laut MEDLINE: Urinary Bladder, Overactive, Acetanilides, Thiazoles, Nerve Growth Factor. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Overactive Bladder Syndrome (OAB) significantly impacts quality of life, necessitating improved diagnostic tools and treatment monitoring. This study explores the potential of neurotrophins, nerve growth factor (NGF), and brain-derived neurotrophic factor (BDNF) as urinary biomarkers in patients with OAB undergoing mirabegron therapy, a β3-adrenergic agonist. This investigation is aimed at providing insights into the potential of neurotrophins to enhance OAB diagnosis and assess treatment efficacy. MATERIALS AND METHODS: Urinary NGF and BDNF levels were measured in 15 healthy controls and 30 patients with OAB. Patients were treated with mirabegron 50 mg once daily. Urinary NGF and BDNF levels were measured by enzyme-linked immunosorbent assay method and normalized by urinary creatinine levels (NGF/Cre and BDNF/Cre). The urinary NGF/Cre and BDNF/Cre levels were compared between controls and patients with OAB and subsequently at baseline and 3 months after mirabegron treatment. Treatment efficacy was assessed with the Indevus Urgency Severity Scale (IUSS) questionnaire. RESULTS: Urinary NGF/Cre and BDNF/Cre levels were significantly higher in patients with OAB than in the controls (p < 0.001 and p = 0.03 respectively). Moreover, NGF/Cre and BDNF/Cre levels significantly decreased post-mirabegron treatment (p < 0.001 and p = 0.005 respectively). Patients with improvement of OAB symptoms after treatment showed lower levels of NGF/Cre at the 3-month evaluation than those with no improvement (p = 0.05). CONCLUSION: Although both NGF/Cre and BDNF/Cre levels were significantly decreased after mirabegron treatment, only NGF/Cre levels were associated with treatment response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Urinary Bladder, OveractiveAcetanilidesThiazolesNerve Growth FactorBrain-Derived Neurotrophic FactorBiomarkersAdrenergic beta-3 Receptor AgonistsHumansFemaleMiddle AgedAdultTreatment OutcomeCase-Control StudiesAgedMale

Stichwörter der Autor:innen

BDNFMirabegronNGFNeurotrophinsOveractive bladder

Substanzen

mirabegronAcetanilidesThiazolesNerve Growth FactorBrain-Derived Neurotrophic FactorBiomarkersAdrenergic beta-3 Receptor AgonistsBDNF protein, humanNGF protein, human

Autor:innen und Institutionen

  • 2nd Department of Obstetrics and Gynecology, Athens University, Medical School, Aretaieion Hospital, Vasilissis Sofias Avenue, 76, 11528, Athens, PC, Greece. an.beta@hotmail.com.
  • 2nd Department of Obstetrics and Gynecology, Athens University, Medical School, Aretaieion Hospital, Vasilissis Sofias Avenue, 76, 11528, Athens, PC, Greece.
  • Division of Endocrinology, Metabolism, and Diabetes, First Department of Pediatrics, School of Medicine, National and Kapodistrian University of Athens, Aghia Sophia Children's Hospital, 11527, Athens, Greece.
  • Department of Pediatric & Adolescent Gynecology, Mitera Children's Hospital, 15123, Athens, Greece.

ORCID-Profile: Anastasia Beta

Zitieren

APA

Beta, A., Giannouli, A., Rizos, D., Mantzou, A., Deligeoroglou, E., & Bakas, P. (2024). Nerve Growth Factor and Brain-Derived Neurotrophic Factor as Potential Biomarkers of Mirabegron Efficacy in Patients with Overactive Bladder Syndrome. International Urogynecology Journal, 35(6), 1317-1322. https://doi.org/10.1007/s00192-024-05809-0

Vancouver

Beta A, Giannouli A, Rizos D, Mantzou A, Deligeoroglou E, Bakas P. Nerve Growth Factor and Brain-Derived Neurotrophic Factor as Potential Biomarkers of Mirabegron Efficacy in Patients with Overactive Bladder Syndrome. International Urogynecology Journal. 2024;35(6):1317-1322. doi:10.1007/s00192-024-05809-0

BibTeX
@article{Beta2024,
  author = {Beta, Anastasia and Giannouli, Aikaterini and Rizos, Demetrios and Mantzou, Aimilia and Deligeoroglou, Efthymios and Bakas, Panagiotis},
  title = {Nerve Growth Factor and Brain-Derived Neurotrophic Factor as Potential Biomarkers of Mirabegron Efficacy in Patients with Overactive Bladder Syndrome},
  journal = {International Urogynecology Journal},
  year = {2024},
  volume = {35},
  number = {6},
  pages = {1317--1322},
  doi = {10.1007/s00192-024-05809-0}
}
Kostenlos starten →